Tilray receives first new cannabis cultivation license in germany under new regulations

Tilray's aphria rx facility in germany granted new cannabis cultivation license, allowing for ~5x production increase and new strains to enhance patient access across the country aphria rx designed with guidance from renowned cannabis grower of broken coast cannabis neumÜnster, germany, july 22, 2024 (globe newswire) -- tilray brands, inc. (“tilray”) (nasdaq: tlry; tsx: tlry), a global leader in cannabis research, cultivation, production, and distribution, today announced that its germany cannabis cultivation facility, aphria rx gmbh (“aphria rx”), has received the first new cannabis cultivation license issued under medcang, germany's new cannabis act. the new cannabis cultivation license allows aphria rx to cultivate and manufacture a broad commercial range of medical cannabis, providing patients with better access to high-quality medical cannabis produced in germany.
TLRY Ratings Summary
TLRY Quant Ranking